Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

JNT Visual / shutterstock.com

ACR/EULAR Release New Classification Criteria for IgG4-Related Disease

Lara C. Pullen, PhD  |  January 16, 2020

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, and diagnosis is challenging. ACR/EULAR classification criteria for IgG4-RD have been developed and validated in a large cohort of patients. These criteria have performed well in tests and should contribute substantially to future clinical, epidemiologic and basic science investigations.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:ACR/EULARClassification CriteriaIgG4 related disease

Tashatuvango / shutterstock.com

Myositis-Specific Antibodies Identified

Mithu Maheswaranathan, MD, & Lisa Criscione-Schreiber, MD, MEd  |  January 16, 2020

The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

Filed under:ConditionsMyositis Tagged with:dermatomyositisidiopathic inflammatory myopathiesidiopathic inflammatory myositismyositis-specific antibodiespolymyositis

Denosumab Tied to Infection Risk

Marilynn Larkin  |  January 13, 2020

NEW YORK (Reuters Health)—The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared with placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals. Talia Diker-Cohen, MD, PhD, of Tel Aviv University, and colleagues searched the literature through May 2019 for randomized controlled trials of denosumab…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesdenosumabInfectionOsteoporosis

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

Natasha Yetman  |  January 7, 2020

NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…

Filed under:Drug Updates Tagged with:costsdrug costDrugs

Malignancy Risk Varies with Treatment in Systemic Necrotizing Vasculitis

Reuters Staff  |  January 7, 2020

NEW YORK (Reuters Health)—The risk of malignancy in patients with systemic necrotizing vasculitis varies according to the treatment received, according to an analysis of five randomized controlled trials. Previous studies reported an increased risk of malignancy in patients with systemic necrotizing vasculitis, and a more recent study from the European Vasculitis Study Group, based on…

Filed under:ConditionsVasculitis Tagged with:malignancysystemic necrotizing vasculitisVasculitis

Male Researchers Call Their Work ‘Novel’ More Often Than Women

Lisa Rapaport  |  December 18, 2019

(Reuters Health)—Male scientists are more likely than their female counterparts to use superlatives, such as first or novel, to describe their work, a new study suggests, and this disparity might contribute to other professional gender gaps, the authors say. The study team analyzed the language used in more than 6 million papers in peer-reviewed medical…

Filed under:Professional TopicsResearch Rheum Tagged with:biasGenderResearch

The 2019 ACR Award Winners & Distinguished Fellows

Carol Patton  |  December 18, 2019

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Filed under:AwardsFrom the CollegeProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingDr. Alfred E. DenioDr. Ali Duarte-GarciaDr. Amr H. SawalhaDr. Brian NolanDr. Bruce CronsteinDr. Dana DiRenzoDr. J. Timothy HarringtonDr. Jean LiewDr. John P. AtkinsonDr. Katherine P. LiaoDr. Marcy B. BolsterDr. Mazen NasrallahDr. Michael A. PaleyDr. Natalie RosenwasserDr. Patricia KatzDr. Polly FergusonDr. Rebecca HabermanDr. Sarah ChenDr. Susan ManziJonathan TL Cheah

Meet the Incoming Arthritis & Rheumatology Editor in Chief, Dr. Daniel Solomon

Kelly Tyrrell  |  December 18, 2019

Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…

Filed under:From the CollegeResearch Rheum Tagged with:Arthritis & RheumatologyDr. Daniel Solomon

Remote Use of the Multidimensional Health Assessment Questionnaire (MDHAQ)

Juan Schmukler, MD, & Theodore Pincus, MD  |  December 18, 2019

The patient medical history is far more prominent in clinical decisions for rheumatology than for many common chronic diseases in which a gold standard biomarker, such as blood pressure or serum glucose, is applicable to diagnosis and management of all individual patients.1 Components of a subjective patient history may be recorded as structured, quantitative, standard,…

Filed under:ConditionsTechnology Tagged with:case reportMultidimensional Health Assessment Questionnaire (MDHAQ)Routine Assessment of Patient Index Data (RAPID)

  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences